Navigation Links
AcelRx Pharmaceuticals Provides Clinical Trial Updates
Date:2/19/2013

he study is designed to assess the ability of sufentanil, delivered through the NanoTab System to control moderate-to-severe post-operative pain over 48 to 72 hours compared to a placebo delivered through the NanoTab System.  The study will also assess the tolerability, safety, and ease of use of the NanoTab System by nurses and patients.  Top-line results are expected in the first quarter of 2013. 
  • A second placebo-controlled Phase 3 trial with the Sufentanil NanoTab PCA System is being conducted at approximately 32 sites in patients following hip or knee replacement surgery.   Targeting enrollment of approximately 400 patients, dosing of the final subject in this study is expected around the end of the first quarter of 2013.  The primary endpoint for both the abdominal and orthopedic placebo-controlled Phase 3 studies is the sum of pain intensity difference to baseline (SPID) over 48 hours. Top-line results should be available for the orthopedic study during the second quarter of 2013.
  • Dosing of the last patient in a Phase 2, placebo-controlled, dose-finding study of the Company's ARX-04 sufentanil NanoTab product has completed.  This study, which began in November 2012, enrolled 101 patients following bunionectomy surgery, randomized into one of three groups: 20 mcg sufentanil NanoTab, 30 mcg sufentanil NanoTab or placebo.  Each dose was administered by healthcare personnel, as requested by the patient, up to a maximum of one dose every hour.  The study is designed to evaluate the ability of sufentanil NanoTabs to manage moderate-to-severe acute pain over the first 12 hours following bunionectomy surgery.  ARX-04 is a sublingual sufentanil product candidate designed to provide a non-invasive, fast-onset treatment of patients with moderate-to-sever acute pain, both on the battlefield and in civilian settings of trauma or injury.  AcelRx is conducting the study at two sites with funding
    '/>"/>

  • SOURCE AcelRx Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4

    Related medicine technology :

    1. AcelRx Appoints Adrian Adams to Board of Directors as Chairman
    2. AcelRx Pharmaceuticals Announces Pricing of Public Offering of Common Stock
    3. AcelRx Pharmaceuticals Announces Proposed Public Offering Of Common Stock
    4. AcelRx Pharmaceuticals to Present at the Piper Jaffray 24th Annual Healthcare Conference
    5. AcelRx Announces Achievement of the Primary End-Point in Phase 3 Comparative Study Involving the Sufentanil NanoTab PCA System and Plans to Hold a Conference Call and Webcast Tomorrow to Discuss Top-Line Results
    6. AcelRx Pharmaceuticals Reports Third Quarter 2012 Financial Results
    7. AcelRx Pharmaceuticals Doses the First Patients in ARX-04 Phase 2 Clinical Study
    8. AcelRx Pharmaceuticals to Hold Third Quarter 2012 Financial Results Conference Call and Webcast on November 6, 2012
    9. AcelRx Pharmaceuticals Hires Mike A. Royal, M.D. as Chief, Clinical Affairs
    10. AcelRx Pharmaceuticals to Present at the UBS Global Life Sciences Conference
    11. AcelRx Pharmaceuticals Receives Fourth and Fifth U.S. Patents for Small-Volume Oral Transmucosal Dosage Forms
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/6/2015)... 6, 2015 Mauna Kea ... multidisciplinary confocal laser endomicroscopy platform, announced today it ... Ministry of Health, Labor and Welfare (MHLW) ... the AQ-Flex 19 miniprobe.   Used ... miniprobe is comprised of a fiber-optic microscope that ...
    (Date:7/6/2015)... 6, 2015   BioClinica®, Inc ., a ... announced that it has acquired a leading global ... Inc. (Medici).  The acquisition includes affiliates MediciGlobal ... also provides a lost-to-follow-up patient locate service ( ... with Medici, BioClinica will offer pharmaceutical ...
    (Date:7/6/2015)... DUBLIN, Ohio , July 6, 2015 ... of The Harvard Drug Group (THDG). A distributor of generic ... and alternate care customers, THDG was owned by Court ... all-cash transaction using existing cash and new debt.  ... , The Harvard Drug Group had revenues of approximately ...
    Breaking Medicine Technology:Mauna Kea Technologies Receives Regulatory Approval for the AQ-Flex 19 Miniprobe in Japan 2Mauna Kea Technologies Receives Regulatory Approval for the AQ-Flex 19 Miniprobe in Japan 3BioClinica Acquires MediciGroup 2BioClinica Acquires MediciGroup 3Cardinal Health Completes Acquisition Of The Harvard Drug Group For $1.115 Billion 2Cardinal Health Completes Acquisition Of The Harvard Drug Group For $1.115 Billion 3
    ... May 10th, 2007 - Antisense,Pharma, a German biopharmaceutical ... announced, that data from the,Phase IIb-study with AP ... 43rd Annual Meeting of the American Society of,Clinical ... Illinois,U.S.A, from June 1st - 5th. , In ...
    ... NICE Appraisal Committee concludes that alteplase is clinically,and ... 2007 – A new clinical appraisal,published by the ... the UK has recommended the use of alteplase,for ... based on,its clinical and cost effectiveness compared with ...
    Cached Medicine Technology:2007 ASCO Annual Meeting: Clinical Results on Phase IIb-study with,AP 12009 in Anaplastic Astrocytoma selected for Poster Discussion 22007 ASCO Annual Meeting: Clinical Results on Phase IIb-study with,AP 12009 in Anaplastic Astrocytoma selected for Poster Discussion 3Actilyse (alteplase) Recommended by National Institute for Health,and Clinical Excellence for Treatment of Acute Ischaemic Stroke 2Actilyse (alteplase) Recommended by National Institute for Health,and Clinical Excellence for Treatment of Acute Ischaemic Stroke 3Actilyse (alteplase) Recommended by National Institute for Health,and Clinical Excellence for Treatment of Acute Ischaemic Stroke 4Actilyse (alteplase) Recommended by National Institute for Health,and Clinical Excellence for Treatment of Acute Ischaemic Stroke 5
    (Date:7/6/2015)... ... 2015 , ... Dr. Lawrence Green is now offering the newly FDA-approved Kybella ... a non-surgical method to dissolve fat cells and is the first of its kind ... the chin, commonly known as a double chin. Dr. Green participated in clinical trials ...
    (Date:7/6/2015)... ... July 06, 2015 , ... Diabetes affects many of us and the ... Americans have diabetes, the majority of which are Type 2. However, eight million do ... one in three, have prediabetes (abnormally high blood sugar levels). Without reductions in blood ...
    (Date:7/5/2015)... ... July 06, 2015 , ... ... market, is excited to announce the next generation of PrimeStar Individual Dental Insurance. ... to now include two network options—Maximum Allowable Charge (MAC) and usual, customary and ...
    (Date:7/5/2015)... ... 05, 2015 , ... World Patent Marketing, a vertically integrated ... invention that effectively removes weeds without harming man and nature. , "The Landscaping ... Creative Director of World Patent Marketing. "It is projected to grow at an ...
    (Date:7/4/2015)... ... ... a real millionaire online can be more difficult. Millionairematchapp.com is a leading ... worries from meeting partners. Recently, the site announced they're publishing of a list ... responded with excitement. , “There's quite a few millionaire dating apps online, but ...
    Breaking Medicine News(10 mins):Health News:Rockville, MD Practice Now Offering New FDA-Approved Non-Surgical Double Chin Treatment 2Health News:115 Million in the U.S. could beat diabetes with the help of a new app 2Health News:Security Life Insurance Company of America Launches the Next Generation of PrimeStar Individual Dental Insurance Plans 2Health News:8 Landscaping Tips That Can Save You Money Thanks To World Patent Marketing's Innovative Landscaping Invention 2Health News:8 Landscaping Tips That Can Save You Money Thanks To World Patent Marketing's Innovative Landscaping Invention 3Health News:8 Landscaping Tips That Can Save You Money Thanks To World Patent Marketing's Innovative Landscaping Invention 4Health News:8 Landscaping Tips That Can Save You Money Thanks To World Patent Marketing's Innovative Landscaping Invention 5Health News:MillionaireMatchapp.com Publishes the Best Millionaire Dating App and Official Dating Site Reviews 2015 2
    ... The Blue Cross and Blue Shield of,Minnesota ... its 13-member board,of directors. The board directs ... improving health in Minnesota and includes five,community ... "Frank brings great experience and passion in ...
    ... Jan. 30 Stryker Corporation,(NYSE: SYK ) announced today that ... February 6, 2008 - 2:20 p.m. Eastern Time ... Medical Device Conference ... the Company,s presentation will be available,on Stryker,s website at http://www.stryker.com ...
    ... published today in FASEB (the journal of the Federation ... Columbia University, including Jeremy Mao of the Columbia College ... porous structures as a drug-delivery vehicle that can help ... titanium. , Instead of being acted upon by the ...
    ... potentially life-threatening disease that affects red blood cells, cells ... part of the SardiNIA Study of Aging, supported by ... the National Institutes of Health, scientists have found a ... why some people with beta-thalassemia seem to be protected ...
    ... Rush University Medical Center in Chicago published this week in ... control the opening and closing of ion channels. This new ... health and disease provides a vital piece of the molecular ... molecular biology at Rush has produced a new explanation for ...
    ... boxes filled with 7,000 unique seed samples from more ... Global Seed Vault, a facility being built on a ... of last resort for humanitys agricultural heritage. , The ... a service to the global community, and a Rome-based ...
    Cached Medicine News:Health News:Fernandez Appointed to Blue Cross Foundation Board 2Health News:Stryker to Present at Investor Conference 2Health News:Porous structures help boost integration of host tissue with implants, study finds 2Health News:Gene variant linked to moderated symptoms of beta-thalassemia 2Health News:Revolution in understanding of ion channel regulation 2Health News:African seed collection first to arrive in Norway on route to Arctic seed vault 2Health News:African seed collection first to arrive in Norway on route to Arctic seed vault 3
    ... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
    ... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
    ... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
    ... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
    Medicine Products: